Radiopharm Theranostics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Radiopharm Theranostics's earnings have been declining at an average annual rate of -44.8%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 44% per year.
Belangrijke informatie
-44.8%
Groei van de winst
-9.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 9.6% |
| Inkomstengroei | 44.0% |
| Rendement op eigen vermogen | -175.3% |
| Nettomarge | -2,448.2% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Radiopharm Theranostics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -48 | 16 | 0 |
| 31 Mar 24 | 4 | -47 | 16 | 0 |
| 31 Dec 23 | 6 | -47 | 16 | 0 |
| 30 Sep 23 | 6 | -41 | 16 | 0 |
| 30 Jun 23 | 6 | -35 | 15 | 0 |
| 31 Mar 23 | 5 | -30 | 15 | 0 |
| 31 Dec 22 | 4 | -26 | 14 | 0 |
| 30 Sep 22 | 2 | -28 | 13 | 0 |
| 30 Jun 22 | 0 | -30 | 12 | 0 |
Kwaliteitswinsten: RAD is currently unprofitable.
Groeiende winstmarge: RAD is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if RAD's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare RAD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: RAD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).
Rendement op eigen vermogen
Hoge ROE: RAD has a negative Return on Equity (-175.3%), as it is currently unprofitable.